Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTIMATE: Secukinumab PDUS Study in PsA
NCT02662985Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Aug 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02662985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662985.